PATENT CLAIM ANALYSIS

Application Number: 15933673
Application Type: Utility
Filing Date: 2018-03
Publication Date: 2018-11
Patent Classification: ["514", "302000"]

Abstract:
Formulations for treating depressive disorders and methods for treating depressive disorders using gaboxadol or a pharmaceutically acceptable salt thereof are provided.

Claim (Index 13):
The method of  claim 12 , wherein the antidepressant includes citalopram, escitalopram, paroxetine, fluvoxamine, sertraline, desvenlafaxine, duloxetine, levomilnacipran, milnacipran, tofenacin, venlafaxine, vilazodone, vortioxetine, etoperidone, trazodone, reboxetine, viloxazine, amitriptyline, amitriptylinoxide, clomipramine, desipramine, dibenzepin, dimetacrine, dosulepin, doxepin, imipramine, lofepramine, melitracen, nitroxazepine, nortriptyline, noxiptiline, pipofezine, protriptyline, trimipramine, amoxapine, maprotiline, mianserin, mirtazapine, setiptiline, socarboxazid, phenelzine, tranylcypromine, selegiline, metralindole, moclobemide, pirlindole, toloxatone, amisulpride, lurasidone, quetiapine, gomelatine, bifemelane, bupropion, ketamine, tandospirone or teniloxazine.

Metadata:
- Claim Count in Document: 5.0
- Percentile: 90.0
- Lexical Diversity: 1.22222
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15680417', '15343690', '15191068', '15700314', '15375735']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.786407493625316
- 35 USC 102 Novelty (BERT): 0.503653697155841
- Combined Prediction Score: 0.7581321139783685
- Mean Citation Score: 237.379544
- Max Citation Score: 243.16272
- Similarity Product: 175.8710682995224

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test